Relapsed/refractory acute myeloid leukemia (R/R AML)
Clinical trials for Relapsed/refractory acute myeloid leukemia (R/R AML) explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory acute myeloid leukemia (R/R AML) trials appear
Sign up with your email to follow new studies for Relapsed/refractory acute myeloid leukemia (R/R AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered t cells target FLT3 in Hard-to-Treat leukemia
Cure Recruiting nowResearchers are testing a new cell therapy called anti-FLT3 CAR-T (HG-CT-1) in adults and children with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatment. The study is a Phase 1 dose-escalation trial, meaning its first goal is to find out…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
Phase 1 • Sponsor: Hemogenyx Pharmaceuticals LLC • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough leukemia: experimental drug BL-M11D1 enters human testing
Disease control Recruiting nowThis early-stage trial tests a new drug called BL-M11D1 in 130 adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Participants must have a specific marker (CD33) on their leu…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC